Canterbury Christ Church University, School of Human and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, UK.
Dept. of Microbial Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH, UK.
Semin Cancer Biol. 2022 Aug;83:77-87. doi: 10.1016/j.semcancer.2021.01.005. Epub 2021 Jan 21.
Despite the advances in treatment using chemotherapy or targeted therapies, due to static survival rates, non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths worldwide. Epigenetic-based therapies have been developed for NSCLC by targeting DNA methyltransferases (DNMTs) and histone-modifying enzymes. However, treatment using single epigenetic agents on solid tumours has been inadequate; whereas, treatment with a combination of DNMTs inhibitors with chemotherapy and immunotherapy has shown great promise. Dietary sources of phytochemicals could also inhibit DNMTs and cancer stem cells, representing a novel and promising way to prevent and treat cancer. Herein, we will discuss the different DNMTs, DNA methylation profiling in NSCLC as well as current demethylating agents in ongoing clinical trials. Therefore, providing a concise overview of future developments in the field of epigenetic therapy in NSCLC.
尽管采用化疗或靶向治疗取得了进展，但由于生存率保持不变，非小细胞肺癌（NSCLC）仍是全球癌症相关死亡的主要原因。已经开发出针对 DNA 甲基转移酶（DNMTs）和组蛋白修饰酶的基于表观遗传的 NSCLC 治疗方法。然而，在实体瘤中使用单一表观遗传药物治疗效果不佳；而联合使用 DNMTs 抑制剂与化疗和免疫疗法显示出巨大的希望。植物化学物质的饮食来源也可以抑制 DNMTs 和癌症干细胞，为预防和治疗癌症提供了一种新颖而有前途的方法。在此，我们将讨论不同的 DNMTs、非小细胞肺癌中的 DNA 甲基化分析以及正在进行的临床试验中的当前去甲基化剂。因此，本文提供了 NSCLC 中表观遗传治疗领域未来发展的简明概述。
